指南与共识生殖医学妇科

依据新国际循证指南诊断的多囊卵巢综合征女性DNA甲基化组解析

Deciphering the DNA methylome in women with PCOS diagnosed using the new international evidence-based guidelines.
指南 / 共识 · Hum Reprod · 2023-01-01

这项横断面病例对照研究纳入34例按新国际循证指南诊断的多囊卵巢综合征(PCOS)患者和36例对照,全血DNA甲基化芯片分析发现264个差异甲基化探针和53个差异甲基化区域,并构建了诊断模型(AUC=0.952);作者指出队列为单中心且样本量相对有限,需更大样本进一步分析。

要点

  • 按新国际循证指南诊断的PCOS患者与对照间鉴定出264个差异甲基化探针和53个差异甲基化区域。
  • 差异甲基化探针显著富集于甘油三酯调节相关生物学过程。
  • 基于LASSO回归的甲基化标志物模型对PCOS诊断具有高准确度(AUC=0.952)。

核心结论

  • 这是首项在新国际循证指南诊断的PCOS女性中鉴定DNA甲基化改变的研究,为新指南的应用提供了新的分子层面见解。

研究设计与样本

  • 横断面病例对照研究,纳入34例按新国际循证指南诊断的PCOS病例和36例对照,共70名女性,对全血样本提取的DNA进行芯片分析。

主要发现

  • PCOS病例与对照间鉴定出264个差异甲基化探针,主要位于基因组基因间区或基因体、CpG开放海位点及功能元件异染色质区。
  • 通路富集分析显示差异甲基化探针显著富集于甘油三酯调节相关生物学过程。
  • 3个差异甲基化探针与PCOS易感基因THADA、AOPEP和TRIML2重叠。
  • 鉴定出53个差异甲基化区域,其注释基因主要富集于同种异体移植排斥、甲状腺激素产生和外周下游信号效应。
  • 2个差异甲基化区域与PCOS易感基因KCNA4和FDFT1密切相关。

关键数值与推荐

  • 新国际循证指南将经阴道超声换能器(频率带宽包含8 MHz)下的多囊卵巢形态(PCOM)阈值定为每侧卵巢≥20个窦卵泡。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 研究队列为单中心。
  • 样本量相对有限。
  • 需要纳入更多参与者进行进一步分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Is there any methylome alteration in women with PCOS who were diagnosed using the new international evidence-based guidelines? SUMMARY ANSWER: A total of 264 differentially methylated probes (DMPs) and 53 differentially methylated regions (DMRs) were identified in patients with PCOS and healthy controls. WHAT IS KNOWN ALREADY: PCOS is a common endocrine disorder among women of reproductive age and polycystic ovarian morphology (PCOM) is one of the main features of the disease. Owing to the availability of more sensitive ultrasound machines, the traditional diagnosis of PCOM according to the Rotterdam criteria (≥12 antral follicles per ovary) is currently debated as there is a risk of overdiagnosis. The new international evidence-based guidelines set the threshold for PCOM as ≥20 antral follicles per ovary when using endovaginal ultrasound transducers with a frequency bandwidth that includes 8 MHz. However, current DNA methylation studies in PCOS are still based on the Rotterdam criteria. This study aimed to explore aberrant DNA methylation in patients diagnosed with PCOS according to the new evidence-based guidelines. STUDY DESIGN, SIZE, DURATION: This cross-sectional case-control study included 34 PCOS cases diagnosed using new international evidence-based guidelines and 36 controls. PARTICIPANTS/MATERIALS, SETTING, METHODS: A total of 70 women, including 34 PCOS cases and 36 controls, were recruited. DNA extracted from whole blood samples of participants were profiled using array technology. Data quality control, preprocessing, annotation, and statistical analyses were performed. Least absolute shrinkage and selection operator (LASSO) regression were used to build a PCOS diagnosis model with DNA methylation sites. MAIN RESULTS AND THE ROLE OF CHANCE: We identified 264 DMPs between PCOS cases and controls, which were mainly located in intergenic regions or gene bodies of the genome, CpG open sea sites, and heterochromatin of functional elements. Pathway enrichment analysis showed that DMPs were significantly enriched in biological processes involved in triglyceride regulation. Three of these DMPs overlapped with the PCOS susceptibility genes thyroid adenoma-associated protein (THADA), aminopeptidase O (AOPEP), and tripartite motif family-like protein 2 (TRIML2). Fifty-three DMRs were identified and their annotated genes were largely enriched in allograft rejection, thyroid hormone production, and peripheral downstream signaling effects. Two DMRs were closely related to the PCOS susceptibility genes, potassium voltage-gated channel subfamily A member 4 (KCNA4) and farnesyl-diphosphate farnesyltransferase 1 (FDFT1). Finally, based on LASSO regression, we built a methylation marker model with high accuracy for PCOS diagnosis (AUC=0.952). LIMITATIONS, REASONS FOR CAUTION: The study cohort was single-center and the sample size was relatively limited. Further analyses with a larger number of participants are required. WIDER IMPLICATIONS OF THE FINDINGS: This is the first study to identify DNA methylation alterations in women with PCOS diagnosed using the new international evidence-based guideline, and it provided new molecular insight into the application of the new guidelines. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by the National Key Research and Development Program of China (2021YFC2700400), Basic Science Center Program of NSFC (31988101), CAMS Innovation Fund for Medical Sciences (2021-I2M-5-001), National Natural Science Foundation of China (32370916, 82071606, 82101707, 82192874, and 31871509), Shandong Provincial Key Research and Development Program (2020ZLYS02), Taishan Scholars Program of Shandong Province (ts20190988), and Fundamental Research Funds of Shandong University. The authors declare no conflicts of interest. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Wang Y, Gao X, Yang Z, et al. Deciphering the DNA methylome in women with PCOS diagnosed using the new international evidence-based guidelines. Hum Reprod. 2023. PMID: 37982419. doi:10.1093/humrep/dead191

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。